Form 4: Bio-Rad Laboratories Executive Receives Stock Grant
Insider Transaction (Form 4)
Sedat Evran, EVP, Global Supply Chain of Bio-Rad Laboratories, Inc., reported multiple transactions in common stock on September 4, 2026.
Summary
- Option exercise/conversion: acquired 1,027 Bio-Rad A Common Stock on September 5, 2026; holds 3,345 after (Direct).
- Tax/exercise-price withholding: disposed of 329 Bio-Rad A Common Stock at $386.11 ($127,030) on September 5, 2026; holds 3,016 after (Direct).
- Option exercise/conversion: acquired 864 Bio-Rad A Common Stock on September 6, 2026; holds 3,880 after (Direct).
- Tax/exercise-price withholding: disposed of 277 Bio-Rad A Common Stock at $386.11 ($106,952) on September 6, 2026; holds 3,603 after (Direct).
- Grant/award: acquired 4,026 Restricted Stock Units on September 4, 2026; holds 4,026 after (Direct).
- Option exercise/conversion: disposed of 1,027 Restricted Stock Units on September 5, 2026; holds 3,083 after (Direct).
- Option exercise/conversion: disposed of 864 Restricted Stock Units on September 6, 2026; holds 1,728 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Sedat Evran — Officer (EVP, Global Supply Chain)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-05 | Option exercise/conversion | Bio-Rad A Common Stock | 1,027 | — | — | 3,345.12 |
| 2026-09-05 | Tax/exercise-price withholding | Bio-Rad A Common Stock | 329 | $386 | $127.0K | 3,016.12 |
| 2026-09-06 | Option exercise/conversion | Bio-Rad A Common Stock | 864 | — | — | 3,880.12 |
| 2026-09-06 | Tax/exercise-price withholding | Bio-Rad A Common Stock | 277 | $386 | $107.0K | 3,603.12 |
| 2026-09-04 | Grant/award | Restricted Stock Units | 4,026 | — | — | 4,026 |
| 2026-09-05 | Option exercise/conversion | Restricted Stock Units | 1,027 | — | — | 3,083 |
| 2026-09-06 | Option exercise/conversion | Restricted Stock Units | 864 | — | — | 1,728 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-05 | Option exercise/conversion (1,027 shares) |
| 2026-09-05 | Tax/exercise-price withholding (329 shares) |
| 2026-09-06 | Option exercise/conversion (864 shares) |
| 2026-09-06 | Tax/exercise-price withholding (277 shares) |
| 2026-09-04 | Grant/award (4,026 shares) |
| 2026-09-05 | Option exercise/conversion (1,027 shares) |
| 2026-09-06 | Option exercise/conversion (864 shares) |
Keywords
insider transaction, Form 4, BIO BIO.B, BIO-RAD LABORATORIES, INC., neutral, Sedat Evran
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.